Iovance Soars 30% to 2024 High as Analysts Cheer Raised Guidance
IOVA has more than doubled off its 52-week low of $1.76 on elevated volume (3.7× avg).
Summary
Iovance shares jumped more than 30% on Tuesday, hitting their highest level since 2024, after the company raised full-year 2026 revenue guidance to $410-$420 million from $350-$370 million, above the $403 million consensus. The move follows strong U.S. demand for Amtagvi and Proleukin. Analysts reacted positively: TD Cowen raised its price target to $16 from $10, Jefferies called the guidance feasible, and Baird noted the increase was substantially expected but will draw investor interest. The next key event is a Q4 data readout from a mid-stage trial of Amtagvi in non-small cell lung cancer.
At the time of this announcement, IOVA was trading at $14.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $1.76 to $15.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.